Published in Headache on April 01, 2002
Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat (2008) 0.90
Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Neurol (2010) 0.80
Are the current IHS guidelines for migraine drug trials being followed? J Headache Pain (2010) 0.79
A review of frovatriptan for the treatment of menstrual migraine. Int J Womens Health (2014) 0.79
Frovatriptan and rizatriptan economic EVAluation: the FREEVA study. J Headache Pain (2013) 0.77
Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. J Headache Pain (2011) 0.76
Managing migraine by patient profile: role of frovatriptan. Patient Prefer Adherence (2016) 0.75
Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache (2002) 2.90
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia (2012) 2.38
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology (2004) 2.22
Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache (2003) 1.97
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Comet 81P/Wild 2 under a microscope. Science (2006) 1.83
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Aspirin is efficacious for the treatment of acute migraine. Headache (2005) 1.55
Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT(1B/1D) agonist efficacy in migraine. Headache (2002) 1.39
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int (2006) 1.16
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt) (2011) 1.15
Incidence and prevalence of dementia in elderly adults with mental retardation without down syndrome. Am J Ment Retard (2004) 1.07
Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard (2004) 1.05
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Res Treat (2012) 1.00
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther (2010) 0.97
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr (2010) 0.96
Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin (2004) 0.96
Bacterial Signal Transduction by Cyclic Di-GMP and Other Nucleotide Second Messengers. J Bacteriol (2016) 0.93
A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™ M) in the treatment of migraine. Headache (2011) 0.91
Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther (2011) 0.90
Stimulant use and HIV risk behavior: the influence of peer support group participation. AIDS Educ Prev (2006) 0.88
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. AIDS Res Hum Retroviruses (2012) 0.87
Breaking the bond between stimulant use and risky sex: a qualitative study. Subst Abus (2010) 0.86
Stanford-Binet & WAIS IQ Differences and Their Implications for Adults with Intellectual Disability (aka Mental Retardation). Intelligence (2010) 0.85
Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study. Pain Med (2009) 0.84
Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat (2011) 0.83
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache (2012) 0.83
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. J Acquir Immune Defic Syndr (2016) 0.83
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS (2011) 0.82
Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache (2004) 0.81
Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc (2012) 0.80
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord (2014) 0.80
Intellectual Disability, Mild Cognitive Impairment, and Risk for Dementia. J Policy Pract Intellect Disabil (2013) 0.80
Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS (2013) 0.79
Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache (2003) 0.79
Real-world experiences in migraine therapy with rizatriptan. Headache (2003) 0.79
Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. Cephalalgia (2013) 0.78
Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. J Antimicrob Chemother (2009) 0.78
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol (2004) 0.77
Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache (2004) 0.77
Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE. Curr HIV Res (2013) 0.76
Expanding access to triptans: assessment of clinical outcome. Headache (2009) 0.75
Freeze core sampling to validate time-lapse resistivity monitoring of the hyporheic zone. Ground Water (2012) 0.75
Consequences of transforming measures of efficacy for acute therapies: 5-HT agonists as a worked example. Headache (2004) 0.75
Sudden unexpected death on challenge courses. Wilderness Environ Med (2002) 0.75
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s). AIDS Res Hum Retroviruses (2010) 0.75